Pharmacology of DB844,an orally active aza analogue of pafuramidine,in a monkey model of second stage human African trypanosomiasis

Novel drugs to treat human african trypanosomiasis (hat) are still urgently needed despite the recent addition of nifurtimox-eflornithine combination therapy (nect) to who model lists of essential medicines against second stage hat,where parasites have invaded the central nervous system (cns). the pharmacology of a potential orally available lead compound,n-methoxy-6-{5-[4-(n-methoxyamidino) phenyl]-furan-2-yl}-nicotinamidine (db844),was evaluated in a vervet monkey model of second stage hat,following promising results in mice. db844 was administered orally to vervet monkeys,beginning 28 days post infection (dpi) with trypanosoma brucei rhodesiense ketri 2537. db844 was absorbed and converted to the active metabolite 6-[5-(4-phenylamidinophenyl)-furanyl-2-yl]-nicotinamide (db820),exhibiting plasma c max values of 430 and 190 nm for db844 and db820,respectively,after the 14th dose at 6 mg/kg qd. a 100-fold reduction in blood trypanosome counts was observed within 24 h of the third dose and,at the end of treatment evaluation performed four days post the last drug dose,trypanosomes were not detected in the blood or cerebrospinal fluid of any monkey. however,some animals relapsed during the 300 days of post treatment monitoring,resulting in a cure rate of 3/8 (37.5%) and 3/7 (42.9%) for the 5 mg/kg×10 days and the 6 mg/kg×14 days dose regimens respectively. these db844 efficacy data were an improvement compared with pentamidine and pafuramidine both of which were previously shown to be non-curative in this model of cns stage hat. these data show that synthesis of novel diamidines with improved activity against cns-stage hat was possible. © 2012 thuita et al.